Company Overview
Company Type: Private Company
Website: moleculight.com
Number of Employees: -
Year Founded: 2012
Total Amount Raised (CAD mm)†: 5.10
Total Rounds of Funding**:4
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
MolecuLight Inc. develops, manufactures, sells, and deploys fluorescence-guided wound imaging technologies for the healthcare industry. The company offers MolecuLight i:X, a wound intelligence device that allows clinicians to visualize bacteria and measure wounds at the point of care. Additionally, the company provides various accessories, such as MolecuLight DarkDrape for optimal fluorescence imaging when room lights cannot be turned off; a MolecuLight Adapter that attaches the DarkDrape to the MolecuLight i:X imaging device; and MolecuLight Woundstickers for wound area measurement with the MolecuLight i:X imaging device. The company has a strategic alliance with Tissue Analytics, Inc. MolecuLight Inc. was incorporated in 2012 and is based in Toronto, Canada, with an additional office in Pittsburgh, Pennsylvania.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Amlani, Anil K. K.
CEO & Director
DaCosta, Ralph 
Founder, CSO & Director
Hirson, Desmond 
Chief Operating Officer
Sandler, Robert 
Chief Marketing Officer
Yannessa, Martha 
Executive Vice President of Sales - Americas

Key Board Members
Name
Title
Ifergan, Sam 
Chairman of the Board
Amlani, Anil K. K.
CEO & Director
DaCosta, Ralph 
Founder, CSO & Director
Bassin, David S.
Independent Director
Foster, Stuart 
Director


Primary Industry Classification
Health Care Equipment


Primary Office Location
425 University Avenue Suite 700 | Toronto, ON | M5G 1T6 | Canada
Phone: 647-362-4684   Fax: 647-362-4730

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
BDC Capital Inc.
Aug-11-2022
Minority
-
Growth
iGan Partners
Jul-11-2013
Unknown
-
Venture
MaRs Discovery District, Investment Arm
-
Unknown
-
-


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-11-2022
Aug-11-2022
Private Placement
Target
MolecuLight Inc.
iGan Partners,BDC Capital Inc.

-
Aug-14-2019
Aug-14-2019
Merger/Acquisition
Seller
Oncology Business of MolecuLight Inc.
photonamic GmbH & Co. KG
MolecuLight Inc.
-
Jan-5-2015
Jan-5-2015
Private Placement
Target
MolecuLight Inc.
iGan Partners

-
May-29-2014
May-29-2014
Private Placement
Target
MolecuLight Inc.
iGan Partners

4.00
Jul-11-2013
Jul-11-2013
Private Placement
Target
MolecuLight Inc.
iGan Partners

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-20-2023
Company Conference Presentations
MolecuLight Inc. Presents at APWCA Wound Week, Sep-20-2023
Jul-06-2023
Executive/Board Changes - Other
Moleculight Inc. Appoints David Bassin to its Board of Directors as an Independent Board Member
May-03-2023
Company Conference Presentations
MolecuLight Inc. Presents at European Wound Management Association (EWMA) 2023 Annual Conference, May-03-2023 through May-05-2023
Apr-27-2023
Client Announcements
Perceptive Solutions, Inc. Announces Partnership with Moleculight Corp., to Deliver A Cloud-Based Wound Management Solution Via Its Woundzoom® Platform
Apr-25-2023
Product-Related Announcements
MolecuLight Inc. Announces the Publication of Skin Pigmentation Impacts the Clinical Diagnosis of Wound Infection

Competitors
HyperMed Imaging, Inc., Kent Imaging Inc., Sanara MedTech Inc. (NasdaqCM:SMTI), Spectral AI, Inc. (NasdaqCM:MDAI), Tissue Analytics, Inc., Woundvision LLC


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
The Insight Partners
The Insight Partners Research Team
May 20, 2022 01:54 AM
MolecuLight Inc.
MolecuLight Inc. in Global Digital Wound Measurement Devices Market to 2028
Notes
5


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
MolecuLight i:X

Key Board Members Details
Name
Title
Phone
Fax
Email
Ifergan, Sam 
Chairman of the Board
647-362-4684
647-362-4730

Amlani, Anil K. K.
CEO & Director
647-362-4684
647-362-4730
aamlani@visualsonics.com
DaCosta, Ralph 
Founder, CSO & Director
647-362-4684
647-362-4730

Bassin, David S.
Independent Director
647-362-4684
647-362-4730

Foster, Stuart 
Director
647-362-4684
647-362-4730

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Amlani, Anil K. K.
CEO & Director
647-362-4684
647-362-4730
aamlani@visualsonics.com
DaCosta, Ralph 
Founder, CSO & Director
647-362-4684
647-362-4730

Hirson, Desmond 
Chief Operating Officer
647-362-4684
647-362-4730

Sandler, Robert 
Chief Marketing Officer
+1.647.362.4684
647-362-4730
rsandler@moleculight.com
Yannessa, Martha 
Executive Vice President of Sales - Americas
647-362-4684
647-362-4730

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
